TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23884909

Group type: COMPARATOR
Intervention: Breath-hold technique
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Free breathing
Number of subjects: 10
Study: 21728272

Group type: EXPERIMENTAL
Intervention: Nebulized Ipraterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nebulized Berodual
Number of subjects: 20
Study: 19367283

Group type: EXPERIMENTAL
Intervention: Lomeguatrib (LM) with temozolomide (TMZ) for 5, 10 or 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Temozolomide (TMZ) alone
Number of subjects: 0
Study: 16926252

Group type: EXPERIMENTAL
Intervention: Testosterone (T) administration in men
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Testosterone plus GH administration in men
Number of subjects: 104

Group type: COMPARATOR
Intervention: GH alone in men
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo alone
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sex steroid(s) alone in women (estrogen/progesterone)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Sex steroid(s) combined with GH in women
Number of subjects: 104
Study: 14741071

Group type: EXPERIMENTAL
Intervention: nateglinide 120 mg t.i.d. for 5 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo for 5 days
Number of subjects: 11
Study: 11533313

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: High protein intake
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual amino acids
Number of subjects: 0
Study: 9107259

Group type: EXPERIMENTAL
Intervention: Combinations of at least two drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substitution or addition of at least two new agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viral load and CD4 measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combinations of two nucleoside analogues plus a third agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two protease inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction in viral load to below the detection level
Number of subjects: 0
Study: 8322143

Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 0
Study: 3004189

Group type: COMPARATOR
Intervention: Standard diet (500 mg cholesterol/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Low-cholesterol diet (250 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Added-bran diet (30 g/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) oil (20% of fat)
Number of subjects: 49
Study: 31952982

Group type: EXPERIMENTAL
Intervention: Urate-lowering therapy (ULT) with Allopurinol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Preventive treatment of asymptomatic and non-severe hyperuricemia
Number of subjects: 13
Study: 30333462

Group type: EXPERIMENTAL
Intervention: FFR determination
Number of subjects: 140
Study: 27141626

Group type: COMPARATOR
Intervention: Intravenous analgesia (IVA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Forearm-injection (forearm-)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Jiaji (EX-B 2)-injection (EX-B 2-1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Zusanli-injection (ST 36-1)
Number of subjects: 80
Study: 23844563

Group type: EXPERIMENTAL
Intervention: dAMB starting on day 4 (group A, n=27)
Number of subjects: 56

Group type: COMPARATOR
Intervention: dAMB starting on day 8 (group B, n=29)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: dAMB starting on day 4 (group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: dAMB starting on day 8 (group B)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: dAMB (both groups)
Number of subjects: 56
Study: 21359666

Group type: EXPERIMENTAL
Intervention: 60‐min polysomnographically‐monitored sleep condition
Number of subjects: 85

Group type: COMPARATOR
Intervention: No-sleep condition
Number of subjects: 85
Study: 19804431

Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study: 18772703

Group type: EXPERIMENTAL
Intervention: Moderate hyperventilation (ETCO2 of 30 mm Hg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normal ventilation (ETCO2 of 40 mm Hg)
Number of subjects: 19
Study: 15781530

Group type: EXPERIMENTAL
Intervention: Mapleson-C MRB
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mapleson-C MRB at PEEP > 10 cm H(2)O
Number of subjects: 10

Group type: COMPARATOR
Intervention: Laerdal MRB at PEEP > 10 cm H(2)O
Number of subjects: 10
Study: 12610182

Group type: EXPERIMENTAL
Intervention: Easy-to-read consent statement
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard consent statement
Number of subjects: 207
Study: 11599829

Group type: EXPERIMENTAL
Intervention: Simultaneous continuous ante‐ and retrograde cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous retrograde blood cardioplegia
Number of subjects: 40
Study: 9306024

Group type: EXPERIMENTAL
Intervention: DMPA
Number of subjects: 50

Group type: COMPARATOR
Intervention: IUD
Number of subjects: 50
Study: 8220405

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2941929

Group type: EXPERIMENTAL
Intervention: 2.5 micrograms recombinant hepatitis B vaccine
Number of subjects: 54
Study: 31541597

Group type: EXPERIMENTAL
Intervention: Intradermal PRP injection and excimer laser
Number of subjects: 52

Group type: COMPARATOR
Intervention: Excimer laser only
Number of subjects: 52
Study: 29738424

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol tablet (10μg)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Vaginal moisturizer
Number of subjects: 302
Study: 27238895

Group type: EXPERIMENTAL
Intervention: Probiotic therapy along with NSAIDs for 12 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo along with NSAIDs for 12 weeks
Number of subjects: 46
Study: 24280856

Group type: EXPERIMENTAL
Intervention: 10 questions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 15 questions
Number of subjects: 180

Group type: COMPARATOR
Intervention: 0 questions
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1 question
Number of subjects: 180

Group type: COMPARATOR
Intervention: 5 questions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Pretest included
Number of subjects: 180
Study: 23834705

Group type: EXPERIMENTAL
Intervention: Filtered light (intervention)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard indoor light (baseline)
Number of subjects: 9
Study: 19911245

Group type: EXPERIMENTAL
Intervention: Minimally invasive subvastus approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional peripatellar approach
Number of subjects: 100
Study: 18212713

Group type: EXPERIMENTAL
Intervention: Diet and strength training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 82
Study: 16483967

Group type: EXPERIMENTAL
Intervention: Aspirin therapy in aCL positive primiparae (49 subjects)
Number of subjects: 924

Group type: COMPARATOR
Intervention: aCL positive status
Number of subjects: 924
Study: 14587042

Group type: EXPERIMENTAL
Intervention: Intermittent anti-D treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine care (glucocorticoid treatment followed by splenectomy)
Number of subjects: 70
Study: 10807447

Group type: EXPERIMENTAL
Intervention: Single chamber atrial pacing (AAI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dual chamber pacing (DDD)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Temporary AAI pacing (in DDD group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both AAI and DDD pacing
Number of subjects: 30
Study: 8635394

Group type: EXPERIMENTAL
Intervention: Phase II screening, randomized phase II studies, and multicenter, comparative, randomized phase III trials
Number of subjects: 0
Study: 31558493

Group type: EXPERIMENTAL
Intervention: Corneal thickness at the apex
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Corneal thickness at the entrance pupil centre
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Corneal thickness at the thinnest point
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Average Pachymetric Progression Index (PPI)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: Maximum Ambrósio relational thickness (ART max)
Number of subjects: 1383
Study: 29217387

Group type: EXPERIMENTAL
Intervention: Individualised duration of elastic compression therapy
Number of subjects: 865

Group type: COMPARATOR
Intervention: Standard duration of elastic compression therapy (24 months)
Number of subjects: 865
Study: 27099242

Group type: EXPERIMENTAL
Intervention: Topical local anaesthesia
Number of subjects: 44

Group type: COMPARATOR
Intervention: Water-based gel (placebo)
Number of subjects: 44
Study: 25897826

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rmhTNF (265 patients)
Number of subjects: 529

Group type: COMPARATOR
Intervention: Chemotherapy alone (264 patients)
Number of subjects: 529
Study: 23629091

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 44
Study: 21970923

Group type: EXPERIMENTAL
Intervention: Stimulation with electrical fields
Number of subjects: 0
Study: 18573765

Group type: EXPERIMENTAL
Intervention: Counterweight weight management programme
Number of subjects: 3400
Study: 16060944

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 883
Study: 11823767

Group type: EXPERIMENTAL
Intervention: Paroxetine initiation at 20 mg/d for 1 month
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care with telephone follow-up at 3 months
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment continued for at least 1 month
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Any antipanic medication at 3 months
Number of subjects: 156
Study: 10782562

Group type: EXPERIMENTAL
Intervention: Atorvastatin (generally 10 mg/day)
Number of subjects: 0
Study: 8746920

Group type: EXPERIMENTAL
Intervention: Buprenorphine (2 mg daily)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Buprenorphine (8 mg daily)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 2390504

Group type: EXPERIMENTAL
Intervention: No. 1 polygalactide (Vicryl)
Number of subjects: 114

Group type: COMPARATOR
Intervention: No. 1 chromic catgut
Number of subjects: 114
Study: 6791054

Group type: EXPERIMENTAL
Intervention: Valproic acid after 10 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control and placebo periods
Number of subjects: 7
Study: 31429207

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT) at 40% of maximal inspiratory pressure (MIP) for 6 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sham Inspiratory Muscle Training at 10% of MIP for 6 weeks
Number of subjects: 84
Study: 30615104

Group type: EXPERIMENTAL
Intervention: Overfeeding + Normal Sleep (8 h sleep opportunity time)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Overfeeding + Sleep Restriction (4 h sleep opportunity time)
Number of subjects: 10
Study: 28743313

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions
Number of subjects: 135

Group type: COMPARATOR
Intervention: Attention control sessions
Number of subjects: 135
Study: 25881382

Group type: EXPERIMENTAL
Intervention: Face mask
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Fixed tongue appliance
Number of subjects: 56
Study: 23666554

Group type: COMPARATOR
Intervention: Benzylpiperazine (BZP) 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trifluoromethylphenylpiperazine (TFMPP) 50 or 60 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzylpiperazine (BZP) 200 mg + Trifluoromethylphenylpiperazine (TFMPP) 100 mg + 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study: 21489843

Group type: EXPERIMENTAL
Intervention: 1-year interdisciplinary intervention including individual counseling every 6 weeks and 25 group seminars (group I; n=22)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group intervention comprising seminars only (group G; n=26)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1-year interdisciplinary intervention (group I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Group intervention (group G)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Direct cost of individual intervention
Number of subjects: 48
Study: 19681868

Group type: EXPERIMENTAL
Intervention: Avizafone (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (11.3 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avizafone (20 mg) with atropine (2 mg) and pralidoxime (350 mg)
Number of subjects: 0
Study: 16434092

Group type: EXPERIMENTAL
Intervention: Core‐Flo (Bisco Inc.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: UniFil Core (GC Corp.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tetric Ceram (Ivoclar‐Vivadent)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Gradia Direct (GC Corp.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Bisfil 2B (Bisco, Inc.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AEliteflo (Bisco, Inc.)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Filtek Flow (3M ESPE)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: UniFil Flow (GC Corp)
Number of subjects: 40
Study: 14764127

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg once daily
Number of subjects: 1281

Group type: EXPERIMENTAL
Intervention: Tolterodine 2 mg twice daily
Number of subjects: 1281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1281
Study: 11720430

Group type: EXPERIMENTAL
Intervention: GM-CSF alone (5 microg kg(‐1), bid, 14 consecutive days every 21 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: GM-CSF with dacarbazine (5 microg kg(‐1), bid, day 2 to day 19 every 21 days and DTIC: 800 mg m(‐2), day 1 of each cycle)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 32
Study: 9164318

Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral treatment (HAART) regimens
Number of subjects: 76

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 76
Study: 8483674

Group type: EXPERIMENTAL
Intervention: Fast task speed, immediate time estimates
Number of subjects: 60

Group type: COMPARATOR
Intervention: Slow task speed, immediate time estimates
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fast task speed, delayed time estimates
Number of subjects: 60

Group type: COMPARATOR
Intervention: Slow task speed, delayed time estimates
Number of subjects: 60
Study: 3667007

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline suspension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-release theophylline tablets
Number of subjects: 0
Study: 26951607

Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Negative Views sub-scale
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Offender Punishment sub-scale
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Deterrence sub-scale
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Hate Crime Beliefs Scale (HCBS) - Victim Harm sub-scale
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Political beliefs and prejudice measures
Number of subjects: 403
Study: 28230262

Group type: EXPERIMENTAL
Intervention: Idarucizumab (5 g dose)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 25523492

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Inhalation sedation with nitrous oxide/oxygen (N2O/O2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (usual behaviour management techniques)
Number of subjects: 45
Study: 23478620

Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Warm-water irrigation
Number of subjects: 341

Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 341
Study: 21953275

Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg) taken with food
Number of subjects: 31

Group type: COMPARATOR
Intervention: Selumetinib (75 mg) taken after fasting for at least 10 hours
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: N-desmethyl-selumetinib (active metabolite)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 31
Study: 18468289

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 5

Group type: COMPARATOR
Intervention: Social reinforcement (playing with friends)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Alone play
Number of subjects: 5

Group type: COMPARATOR
Intervention: Quiet time (resting)
Number of subjects: 5
Study: 16636492

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 12005141

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine digluconate mouthrinse
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sterile water mouthrinse
Number of subjects: 20
Study: 10509320

Group type: EXPERIMENTAL
Intervention: Primary combined‐modality therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative combined‐modality therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of radiation (INT 0123 trial)
Number of subjects: 0
Study: 7595900

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1819290

Group type: EXPERIMENTAL
Intervention: Toothbrush/paste
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Massularia acuminata chewing stick
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Sorindeia warneckei chewing stick
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 6637554

Group type: EXPERIMENTAL
Intervention: Hypospadiacs
Number of subjects: 33

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 33
Study: 31771594

Group type: EXPERIMENTAL
Intervention: Persistent HPV16 infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sum of viral load for all hrHPV types
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persistent HPV16 infection with CIN2+
Number of subjects: 0

Group type: COMPARATOR
Intervention: Persistent infection without CIN2+ lesions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sum of all hrHPV types with persistent infection and CIN2+
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sum of all hrHPV types without CIN2+
Number of subjects: 0
Study: 31006680

Group type: EXPERIMENTAL
Intervention: Drought driven food insecurity assessment
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Malnutrition assessment in under five children
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment
Number of subjects: 422
Study: 29020106

Group type: EXPERIMENTAL
Intervention: Tai Chi training for 6 months
Number of subjects: 87

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Tai Chi experts
Number of subjects: 87
Study: 25383451

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 378
Study: 23524528

Group type: EXPERIMENTAL
Intervention: CRT plus implantable cardioverter defibrillator
Number of subjects: 1820

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator-only
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Every 5-point increase in RV fractional area change
Number of subjects: 1820

Group type: EXPERIMENTAL
Intervention: Baseline tricuspid regurgitant velocity
Number of subjects: 1820
Study: 21816056

Group type: EXPERIMENTAL
Intervention: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis)
Number of subjects: 1100
Study: 19346565

Group type: EXPERIMENTAL
Intervention: Integrated HIV primary care, mental health, and substance abuse services
Number of subjects: 431

Group type: COMPARATOR
Intervention: Care-as-usual (control group)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Integrated interventions
Number of subjects: 431
Study: 16776026

Group type: EXPERIMENTAL
Intervention: Care coordination model
Number of subjects: 28
Study: 15476990

Group type: EXPERIMENTAL
Intervention: Evidence-based education package (information booklet and verbal teaching by a urology nurse)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no education package)
Number of subjects: 55
Study: 11293750

Group type: EXPERIMENTAL
Intervention: New method of rapid dilation using a stiffenable metal guide wire of 6.6 Fr and plastic bougies
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional percutaneous transhepatic biliary drainage (PTBD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (new method and conventional approach)
Number of subjects: 60
Study: 9385482

Group type: EXPERIMENTAL
Intervention: Sparfloxacin 400 mg orally once followed by 200 mg orally daily for 10 days (n = 168)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Cefaclor 500 mg orally every 8 hours for 10 days (n = 162)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Sparfloxacin and Cefaclor
Number of subjects: 330
Study: 7961014

Group type: EXPERIMENTAL
Intervention: Continuous low dose rate iridium implants following 50 Gy whole breast irradiation
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Co-60 beams
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Clinical T-size over 20 mm
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Follow-up period
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Dose rate (mean 0.57, range 0.26-0.89 Gy/h)
Number of subjects: 404
Study: 3036020

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30615583

Group type: EXPERIMENTAL
Intervention: Yoga-based lifestyle intervention (including diet)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 260